DAWEX
8.2.2024 08:31:33 CET | Business Wire | Press release
Today marks the signature of Data4Industry-X, the trusted, secure, compliant and sovereign data exchange environment for the Industry sector, under the control of the industry. Initially addressing the automotive and power generation industry challenges, the solution Data4Industry-X aims at improving competitiveness and reducing the carbon footprint of major global industrial organizations with operations spread across multiple countries. Data4Industry-X will enable organizations to innovate and operate services on distributed data, coming from various factories, organizations or countries, while keeping control over the data produced locally and abroad.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240205958581/en/
The Trusted Data Exchange Solution for Industry (Credits: Dawex)
Supported by the French government’s France 2030 initiative and the European program Next Generation1, and with the endorsement of AIF (Alliance pour l’industrie du futur), Data4Industry-X relies on the technological and industrial expertise of Dawex, Schneider Electric, Valeo, CEA, and Prosyst to deliver a powerful response to support the Industry digital transformation and capitalize on the high potential of industrial data.
Contributing to the international Manufacturing-X initiative, Data4Industry-X is a trusted and secure data exchange solution, implementing the Gaia-X de facto standards and designed in compliance with the new European data regulations, such as the Data Act.
Addressing the Industry challenge of data exchange in decentralized manufacturing, Data4Industry-X will improve efficiency and productivity, accelerate data-driven innovation, boost competitiveness and minimize carbon footprint.
In a context of heavy digital transformation and industrial sovereignty, Data4Industry-X will contribute to improving Europe’s competitiveness to ultimately foster a compelling and sustainable Industry ecosystem by leveraging the full potential of broad cross-border, cross-company, cross-factory industrial data exchanges.
“The Industry sector is a strategic pillar to the European and global economy. Accelerating data exchange across trusted data spaces will definitely have a transformative impact on industrial organizations, driving innovation and responsible growth,” said Laurent Lafaye, Dawex co-CEO. “We are extremely happy to bring Dawex technology and expertise to the deployment of Data4Industry-X, and empower the Industry to foster a resilient and sustainable Industry ecosystem,” concluded Mr. Lafaye.
“Trusted data exchange is fundamental to driving collaboration, forging partnerships, and establishing new industrial models. Those new digital models are essentials for accelerating the transformation toward a more resilient, sustainable, and high-performing industrial eco-system. Schneider Electric takes pride in contributing with our industrial digital transformation expertise to develop Data4Industry-X as a flagship project of International Manufacturing-X,“ said Marc LAFONT, Innovation and Upstream Marketing VP, Industrial Automation Business Unit, Schneider Electric.
Romain Bruniaux, VP Industry, Valeo said: “Data4Industry-X is a collaborative trusted and secure data exchange solution, It offers amazing opportunities to speed up digitalization of our manufacturing process while drastically reducing our scope 1 & 2 CO2 direct and indirect emissions. With Data4Industry-X, Valeo will have the necessary data to support and direct its actions to meet our commitment to be carbon neutral by 2050.”
“Data4Industry-X capitalizes on national technologies that have already proved their worth in industry. Given the international state of the art in the field, with few operational tools known to date, Europe has a chance to take the lead in data exchange for Manufacturing,” said Alexandre Bounouh, Director CEA List, Carnot Institute.
“Collective intelligence, shared vision, teams’ symbiosis: the ingredients come together for the success of Data4Industry-X,” says Abdallah Asse, Prosyst CEO.
About Dawex
Dawex is the leader in data exchange solutions to distribute or share data products, with trust, for any business case. With the Dawex solution Data Exchange Platform, organizations create data ecosystems based on data marketplaces and data hubs that meet regulatory requirements, address traceability and security challenges. Awarded Technology Pioneer by the World Economic Forum, Dawex is the initiator of an international standardization program on “Trusted Data Transaction”. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
About Schneider Electric
Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On. Our mission is to be your digital partner for Sustainability and Efficiency. We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries. We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values. www.se.com
About Valeo
As a technology company and partner to all automakers and new mobility players, Valeo is innovating to make mobility cleaner, safer and smarter. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group's growth drivers. Learn more: https://www.valeo.com/en/
About CEA-List
The CEA-List, based in Paris-Saclay and Grenoble, is a CEA technology research institute dedicated to intelligent digital systems. From artificial intelligence to digital trust, its research applies to a wide range of fields, from the industry of the future to digital health, contributing to the industrial competitiveness of its partners through innovation and technology transfer. CEA-List has been a "Carnot Institute" since 2006. Learn more: https://www.cea.fr/english
About Prosyst
Prosyst develops and markets innovative solutions (hardware and software) stimming from its strong commitment in Research and Development and offers global approaches for design, setup, simulation, data collect and management, diagnosis and performance, to support its customers all along the automated systems life cycle. Prosyst addresses all sectors of activity and counts among others, clients like Stellantis, Renault, SNCF, EDF, Naval Group, … Learn more: https://www.prosyst.fr/
1Supported by the European Union - Next Generation EU “France Relance” program
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205958581/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom